Vistagen Therapeutics, Inc. (VTGN) stock
Close on Nov 11, 2026Market cap $8.33MP/E –Yield –
Vistagen Therapeutics, Inc. reported revenue of $2.50M for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $8.33M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.33M
- P/E ratio
- –
- Price to sales
- 3.33
- Price to book
- 0.34
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.50M
- Net income
- -$67.62M
- EPS, diluted
- -$1.67
- Book value per share
- $0.57
- Diluted shares
- 43M
Trading
- Next earnings
- Nov 12, 2026 (estimated, after the close)
- Previous close
- $0.18
- Open
- $0.19
- Day's range
- $0.18 – $0.19
- Volume
- 336,250
- Average volume (20 days)
- 759,094
- Beta (5 years)
- 1.31
- 52-week range
- $0.16 – $5.14
- RSI (14 days)
- 46.1
- Volatility (1 year)
- 142.6%
- Relative volume
- 0.04×
- WACC
- 11.4%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | VTGN | S&P 500 | Difference | VTGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.5% | -2.4% | −18.0 pts | ||
| 3 months | -30.2% | -1.2% | −29.1 pts | ||
| Year to date | -71.6% | +12.3% | −83.9 pts | ||
| 1 year | -95.3% | +12.4% | −107.8 pts | ||
| 3 years | -92.7% | +78.8% | −171.5 pts | -58.2% | +21.4% |
| 5 years | -99.7% | +75.2% | −174.9 pts | -69.4% | +11.9% |
| 10 years | -99.8% | +311.1% | −410.9 pts | -47.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vistagen Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- News
- News
- Results
- Update
About Vistagen Therapeutics
Pharmaceutical Preparations
Vistagen is a late clinical-stage biotechnology company engaged in the research, development, and potential commercialization of novel treatments for central nervous system and women's health conditions. The company's pipeline centers on intranasal pherine product candidates designed with a non-systemic neurocircuitry-focused mechanism of action. Its drug candidates include fasedienol for social anxiety disorder, itruvone for major depressive disorder, refisolone for menopausal vasomotor symptoms and premenstrual dysphoric disorder, PH15 for cognitive and psychomotor impairment caused by mental fatigue, and PH284 for cancer cachexia. The company also investigates AV-101, an oral prodrug targeting neurological conditions. Its target population comprises patients experiencing these severe conditions, including individuals suffering from social phobias, depression, and menopausal hot flashes.
Company profile, executives and historyVistagen Therapeutics stock: common questions
What is Vistagen Therapeutics's stock price?
VTGN closed at $0.19 on Nov 11, 2026, up 2.57% on the day. Over the past 52 weeks it traded between $0.16 and $5.14.
What is Vistagen Therapeutics's market cap?
Vistagen Therapeutics was worth $8.33M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is VTGN's P/E ratio?
Vistagen Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.67), so it has no meaningful P/E ratio.
How much revenue does Vistagen Therapeutics make?
Vistagen Therapeutics reported revenue of $2.50M for the twelve months to Jun 30, 2026.
Does Vistagen Therapeutics pay a dividend?
No. Vistagen Therapeutics has not paid a cash dividend over the last twelve months.
When does Vistagen Therapeutics report earnings next?
Vistagen Therapeutics is expected to report Q2 FY2027 results on Nov 12, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has VTGN stock performed over the past year?
Including dividends, VTGN returned -95.3% over the past year, against +12.4% for the S&P 500.
How many VTGN shares are sold short?
2M shares were sold short at the latest FINRA report, 5.64% of the float, or 3.4 days of average trading volume.
Who are Vistagen Therapeutics's competitors?
Companies most similar to Vistagen Therapeutics by business, industry and size include UPB, NRXP, DNTH, XENE, LPCN.
See a number that looks wrong?